← Back to Search

Other

AG-920 for Local Anesthesia

Phase 3

Waitlist Available

Research Sponsored by American Genomics, LLC

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from randomization through study completion (up to 4 days following treatment); 90 days following treatment for subjects participating in specular microscopy.

Awards & highlights

Study Summary

This trial is testing a new eye drop to see if it is safe for use.

Eligible Conditions

Local Anesthesia

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from randomization through study completion (up to 4 days following treatment); 90 days following treatment for subjects participating in specular microscopy.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from randomization through study completion (up to 4 days following treatment); 90 days following treatment for subjects participating in specular microscopy.

This trial's timeline: 3 weeks for screening, Varies for treatment, and from randomization through study completion (up to 4 days following treatment); 90 days following treatment for subjects participating in specular microscopy. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of participants with Treatment Emergent Adverse Events (TEAEs)

Secondary outcome measures

Mean change from baseline in corneal endothelial cell density after treatment with AG-920

Side effects data

From 2020 Phase 3 trial • 120 Patients • NCT04513652

53%

Instillation Site Pain

Dysgeusia

Conjunctival Hyperaemia

100%

80%

60%

40%

20%

Study treatment Arm

AG-920

Placebo

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: AG-920Experimental Treatment1 Intervention

Articaine Sterile Topical Ophthalmic Solution (AG-920) is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%.

Group II: PlaceboPlacebo Group1 Intervention

Placebo Sterile Topical Ophthalmic Solution

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

AG-920

2022

Completed Phase 3

~570

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

American Genomics, LLCLead Sponsor

4 Previous Clinical Trials

315 Total Patients Enrolled

Martin Uram, MDStudy DirectorMedical Expert

4 Previous Clinical Trials

315 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What have researchers found about the safety of AG-920 in human subjects?

"AG-920, which is currently in Phase 3 testing, has received a safety score of 3 from our analysts. This is due to the presence of supporting efficacy data as well as multiple rounds of safety data."

Answered by AI

Are people with the required qualifications able to participate in this research right now?

"No, this study is not recruiting patients at this moment. The first posting was on July 30th, 2022 and the most recent update was on October 21st, 2022. It is worth mentioning that there are 309 other clinical trials that are actively seeking participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution

2022. "A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05501860.